Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Phuong Nguyen, Torge Rempe, Reza Forghani
Multiple sclerosis (MS) is a chronic inflammatory disease of the nervous system. MR imaging findings play an integral part in establishing diagnostic hallmarks of the disease during initial diagnosis and evaluating disease status. Multiple iterations of diagnostic criteria and consensus guidelines are put forth by various expert groups incorporating imaging of the brain and spine, and efforts have been made to standardize imaging protocols for MS. Emerging ancillary imaging findings have also attracted increasing interests and should be sought for on radiologic examination...
May 2024: Magnetic Resonance Imaging Clinics of North America
#2
JOURNAL ARTICLE
Agustin Pappolla, Cristina Auger, Augusto Sao-Aviles, Carmen Tur, Marta Rodriguez-Barranco, Álvaro Cobo-Calvo, Neus Mongay-Ochoa, Breogán Rodríguez-Acevedo, Ana Zabalza, Luciana Midaglia, Pere Carbonell-Mirabent, Rene Carvajal, Joaquín Castilló-Justribó, Nathane Braga, Luca Bollo, Angela Vidal-Jordana, Georgina Arrambide, Carlos Nos, Annalaura Salerno, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Mar Tintoré, Alex Rovira, Xavier Montalban, Jordi Río
BACKGROUND: Limited data exist regarding treatment response prediction to oral disease-modifying therapies (DMTs) in multiple sclerosis (MS). OBJECTIVES: We assessed the capacity of available scoring systems to anticipate disease activity parameters in naïve relapsing-remitting MS (RRMS) patients initiating daily oral DMTs, hypothesizing that they exhibit different predictive potentials. METHODS: We conducted a retrospective study and applied the Rio Score (RS), modified Rio Score (mRS), and MAGNIMS Score 12 months after DMT initiation...
March 29, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#3
JOURNAL ARTICLE
Andrea Lazzarotto, Mariem Hamzaoui, Matteo Tonietto, Anne-Laure Dubessy, Michael Khalil, Lukas Pirpamer, Stefan Ropele, Christian Enzinger, Marco Battaglini, Maria Laura Stromillo, Nicola De Stefano, Massimo Filippi, Maria Assunta Rocca, Paolo Gallo, Claudio Gasperini, Bruno Stankoff, Benedetta Bodini
Cortical myelin loss and repair in multiple sclerosis (MS) have been explored in neuropathological studies, but the impact of these processes on neurodegeneration and the irreversible clinical progression of the disease remains unknown. Here, we evaluated in-vivo cortical demyelination and remyelination in a large cohort of people with all clinical phenotypes of MS followed-up for 5 years using magnetization transfer imaging (MTI), a technique that has been shown to be sensitive to myelin content changes in the cortex...
January 24, 2024: Brain
#4
MULTICENTER STUDY
Angela Vidal-Jordana, Alex Rovira, Willem Calderon, Georgina Arrambide, Joaquín Castilló, Dulce Moncho, Kimia Rahnama, Sara Collorone, Ahmed T Toosy, Olga Ciccarelli, Athina Papadopoulou, Nuria Cerdá-Fuertes, Johanna M Lieb, Serena Ruggieri, Carla Tortorella, Claudio Gasperini, Alvino Bisecco, Rocco Capuano, Antonio Gallo, Andrea De Barros, Annalaura Salerno, Cristina Auger, Jaume Sastre-Garriga, Mar Tintore, Xavier Montalban
BACKGROUND AND OBJECTIVES: The optic nerve is not one of the areas of the CNS that can be used to demonstrate dissemination in space (DIS) within the 2017 McDonald criteria for the diagnosis of multiple sclerosis (MS). Objectives were (1) to assess whether optic nerve-MRI (ON-MRI), optical coherence tomography (OCT), and visual evoked potentials (VEP) detect optic nerve involvement in clinically isolated syndrome (CIS) and (2) to evaluate the contribution of the optic nerve topography to the current diagnostic criteria in a prospective, multicenter cohort...
January 9, 2024: Neurology
#5
JOURNAL ARTICLE
Alessandro Cagol, Rosa Cortese, Muhamed Barakovic, Sabine Schaedelin, Esther Ruberte, Martina Absinta, Frederik Barkhof, Massimiliano Calabrese, Marco Castellaro, Olga Ciccarelli, Sirio Cocozza, Nicola De Stefano, Christian Enzinger, Massimo Filippi, Maciej Jurynczyk, Pietro Maggi, Nima Mahmoudi, Silvia Messina, Xavier Montalban, Jacqueline Palace, Giuseppe Pontillo, Anne-Katrin Pröbstel, Maria A Rocca, Stefan Ropele, Àlex Rovira, Menno M Schoonheim, Piotr Sowa, Eva Strijbis, Mike P Wattjes, Maria Pia Sormani, Ludwig Kappos, Cristina Granziera
IMPORTANCE: Multiple sclerosis (MS) misdiagnosis remains an important issue in clinical practice. OBJECTIVE: To quantify the performance of cortical lesions (CLs) and central vein sign (CVS) in distinguishing MS from other conditions showing brain lesions on magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective, cross-sectional multicenter study, with clinical and MRI data acquired between January 2010 and May 2020...
December 11, 2023: JAMA Neurology
#6
JOURNAL ARTICLE
Serena Ruggieri, Luca Prosperini, Sarmad Al-Araji, Pietro Osvaldo Annovazzi, Alvino Bisecco, Olga Ciccarelli, Nicola De Stefano, Massimo Filippi, Vinzenz Fleischer, Nikos Evangelou, Christian Enzinger, Antonio Gallo, Afagh Garjani, Sergiu Groppa, Shalom Haggiag, Michael Khalil, Matteo Lucchini, Massimiliano Mirabella, Xavier Montalban, Carlo Pozzilli, Paolo Preziosa, Jordi Río, Maria A Rocca, Alex Rovira, Maria L Stromillo, Mauro Zaffaroni, Carla Tortorella, Claudio Gasperini
BACKGROUND: The assessment of treatment response is a crucial step for patients with relapsing-remitting multiple sclerosis on disease-modifying therapies (DMTs). We explored whether a scoring system developed within the MAGNIMS (MRI in Multiple Sclerosis) network to evaluate treatment response to injectable drugs can be adopted also to oral DMTs. METHODS: A multicentre dataset of 1200 patients who started three oral DMTs (fingolimod, teriflunomide and dimethyl fumarate) was collected within the MAGNIMS network...
September 29, 2023: Journal of Neurology, Neurosurgery, and Psychiatry
#7
JOURNAL ARTICLE
Arpit Agrawal, M V Padma Srivastava, Rohit Bhatia, Vinay Goyal, Mamta Bhushan Singh, Venugopalan Y Vishnu, Anuj Prabhakar
Azathioprine (AZA) has demonstrated efficacy in multiple randomized control trials (RCTs) for Relapsing-Remitting Multiple Sclerosis (RRMS). However, we still need comparative real-world data with other first-line disease-modifying therapies (DMTs). We aimed to assess AZA's effectiveness regarding relapses, disability progression, time to the first relapse, magnetic resonance imaging (MRI) activity, and safety compared with other approved first-line DMTs in an Indian population in a real-world setting. We conducted a single-center prospective study of treatment-naive RRMS patients between 2017 and 2019...
August 27, 2023: Brain Sciences
#8
JOURNAL ARTICLE
Gilles Edan, Emmanuelle Le Page
After more than 2 decades of recommending an escalating strategy for the treatment of most patients with multiple sclerosis, there has recently been considerable interest in the use of high-efficacy therapies in the early stage of the disease. Early intervention with induction/high-efficacy disease-modifying therapy may have the best risk-benefit profile for patients with relapsing-remitting multiple sclerosis who are young and have active disease, numerous focal T2 lesions on spinal and brain magnetic resonance imaging, and no irreversible disability...
October 2023: Drugs
#9
JOURNAL ARTICLE
Vinzenz Fleischer, Gabriel Gonzalez-Escamilla, Deborah Pareto, Alex Rovira, Jaume Sastre-Garriga, Piotr Sowa, Einar A Høgestøl, Hanne F Harbo, Barbara Bellenberg, Carsten Lukas, Serena Ruggieri, Claudio Gasperini, Tomas Uher, Manuela Vaneckova, Stefan Bittner, Ahmed E Othman, Sara Collorone, Ahmed T Toosy, Sven G Meuth, Frauke Zipp, Frederik Barkhof, Olga Ciccarelli, Sergiu Groppa
The identification of prognostic markers in early multiple sclerosis (MS) is challenging and requires reliable measures that robustly predict future disease trajectories. Ideally, such measures should make inferences at the individual level to inform clinical decisions. This study investigated the prognostic value of longitudinal structural networks to predict five-year EDSS progression in patients with relapsing-remitting MS (RRMS). We hypothesized that network measures, derived from magnetic resonance imaging (MRI), outperform conventional MRI measurements at identifying patients at risk of developing disability progression...
August 29, 2023: Brain
#10
JOURNAL ARTICLE
B Testud, N Fabiani, S Demortière, S Mchinda, N L Medina, J Pelletier, M Guye, B Audoin, J P Stellmann, V Callot
BACKGROUND AND PURPOSE: The detection of spinal cord lesions in patients with MS is challenging. Recently, the 3D MP2RAGE sequence demonstrated its usefulness at 3T. Benefiting from the high spatial resolution provided by ultra-high-field MR imaging systems, we aimed to evaluate the contribution of the 3D MP2RAGE sequence acquired at 7T for the detection of MS lesions in the cervical spine. MATERIALS AND METHODS: Seventeen patients with MS participated in this study...
August 10, 2023: AJNR. American Journal of Neuroradiology
#11
JOURNAL ARTICLE
Eloy Martinez-Heras, Elisabeth Solana, Francesc Vivó, Elisabet Lopez-Soley, Alberto Calvi, Salut Alba-Arbalat, Menno M Schoonheim, Eva M Strijbis, Hugo Vrenken, Frederik Barkhof, Maria A Rocca, Massimo Filippi, Elisabetta Pagani, Sergiu Groppa, Vinzenz Fleischer, Robert A Dineen, Barbara Bellenberg, Carsten Lukas, Deborah Pareto, Alex Rovira, Jaume Sastre-Garriga, Sara Collorone, Ferran Prados, Ahmed Toosy, Olga Ciccarelli, Albert Saiz, Yolanda Blanco, Sara Llufriu
BACKGROUND: We aimed to describe the severity of the changes in brain diffusion-based connectivity as multiple sclerosis (MS) progresses and the microstructural characteristics of these networks that are associated with distinct MS phenotypes. METHODS: Clinical information and brain MRIs were collected from 221 healthy individuals and 823 people with MS at 8 MAGNIMS centres. The patients were divided into four clinical phenotypes: clinically isolated syndrome, relapsing-remitting, secondary progressive and primary progressive...
June 15, 2023: Journal of Neurology, Neurosurgery, and Psychiatry
#12
JOURNAL ARTICLE
Jérôme Hodel, Meike W Vernooij, Mona K Beyer, Mariasavina Severino, Xavier Leclerc, Alain Créange, Abir Wahab, Neesmah Badat, Sarah Tolédano, Luc van den Hauwe, Ana Ramos, Antonella Castellano, Alexandre Krainik, Tarek Yousry, Àlex Rovira
OBJECTIVES: To evaluate compliance with the available recommendations, we assessed the current clinical practice of imaging in the evaluation of multiple sclerosis (MS). METHODS: An online questionnaire was emailed to all members and affiliates. Information was gathered on applied MR imaging protocols, gadolinium-based contrast agents (GBCA) use and image analysis. We compared the survey results with the Magnetic Resonance Imaging in MS (MAGNIMS) recommendations considered as the reference standard...
May 18, 2023: European Radiology
#13
JOURNAL ARTICLE
Anna Maunula, Juha Martola, Sari Atula, Sini M Laakso, Pentti J Tienari
BACKGROUND: There is an absence of data from large population-based cohort studies on the incidence of radiologically isolated syndrome (RIS). We investigated the incidence of RIS and the subsequent risk for multiple sclerosis (MS). METHODS: We conducted a population-based, retrospective cohort study using a data lake-based analysis of digitalized radiology reports. We screened all brain and spinal cord MRIs in people aged 16-70 during the years 2005-2010 (n=102 224) using optimized search terms to detect cases with RIS...
May 9, 2023: European Journal of Neurology
#14
JOURNAL ARTICLE
Sandra D Cassard, Kathryn C Fitzgerald, Peiqing Qian, Susan A Emrich, Christina J Azevedo, Andrew D Goodman, Elizabeth A Sugar, Daniel Pelletier, Emmanuelle Waubant, Ellen M Mowry
BACKGROUND: Vitamin D insufficiency is associated with risk of multiple sclerosis (MS) relapse; whether supplementation influences prognosis is unknown. The Vitamin D to Ameliorate MS (VIDAMS) trial aimed to determine if high dose (5000 International Units (IU)/day) versus low dose (600 IU/day) vitamin D3, added to daily glatiramer acetate (GA), reduced the risk of clinical relapse in people with established relapsing remitting MS (RRMS) over 96 weeks. METHODS: VIDAMS is a randomised, phase 3, double-blind, multi-centre, controlled trial conducted at sixteen neurology clinics in the United States...
May 2023: EClinicalMedicine
#15
JOURNAL ARTICLE
Shivam Patel, Ian Dimaandal, Tyler Kuhns, Marina Creed, Abner Gershon, Ivan Wolansky, Jaime Imitola, Leo Wolansky
BACKGROUND AND PURPOSE: Magnetic resonance imaging (MRI) plays a key role in diagnosing and monitoring multiple sclerosis (MS). Double inversion recovery (DIR) is a pulse sequence that has proven highly effective at detecting cortical lesions but is understudied in the spinal cord. We hypothesize that DIR images obtained during brain MRI can be of value in assessing the upper spinal cord of MS patients. METHODS: We retrospectively examined brain MRI exams of 64 patients with established MS, who had also undergone cervical spine MRI...
March 28, 2023: Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging
#16
JOURNAL ARTICLE
Rosa Cortese, Marco Battaglini, Ferran Prados, Alessia Bianchi, Lukas Haider, Anu Jacob, Jacqueline Palace, Silvia Messina, Friedemann Paul, Jens Wuerfel, Romain Marignier, Françoise Durand-Dubief, Carolina de Medeiros Rimkus, Dagoberto Callegaro, Douglas Kazutoshi Sato, Massimo Filippi, Maria Assunta Rocca, Laura Cacciaguerra, Alex Rovira, Jaume Sastre-Garriga, Georgina Arrambide, Yaou Liu, Yunyun Duan, Claudio Gasperini, Carla Tortorella, Serena Ruggieri, Maria Pia Amato, Monica Ulivelli, Sergiu Groppa, Matthias Grothe, Sara Llufriu, Maria Sepulveda, Carsten Lukas, Barbara Bellenberg, Ruth Schneider, Piotr Sowa, Elisabeth G Celius, Anne-Katrin Proebstel, Özgür Yaldizli, Jannis Müller, Bruno Stankoff, Benedetta Bodini, Luca Carmisciano, Maria Pia Sormani, Frederik Barkhof, Nicola De Stefano, Olga Ciccarelli
MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing for MOG antibodies is unavailable or shows uncertain results. We aimed to identify MRI and clinical markers that differentiate non-acute MOG-antibody disease from aquaporin 4 (AQP4)-antibody neuromyelitis optica spectrum disorder and relapsing remitting multiple sclerosis, guiding in the identification of patients with MOG-antibody disease in clinical practice...
June 1, 2023: Brain
#17
JOURNAL ARTICLE
Maria A Rocca, Paola Valsasina, Alessandro Meani, Claudio Gobbi, Chiara Zecca, Frederik Barkhof, Menno M Schoonheim, Eva M Strijbis, Hugo Vrenken, Antonio Gallo, Alvino Bisecco, Olga Ciccarelli, Marios Yiannakas, Alex Rovira, Jaume Sastre-Garriga, Jacqueline Palace, Lucy Matthews, Achim Gass, Philipp Eisele, Carsten Lukas, Barbara Bellenberg, Monica Margoni, Paolo Preziosa, Massimo Filippi
OBJECTIVES: To evaluate the combined contribution of brain and cervical cord damage in predicting 5-year clinical worsening in a multicentre cohort of definite multiple sclerosis (MS) patients. METHODS: Baseline 3.0T brain and cervical cord T2-weighted and three-dimensional T1-weighted MRI was acquired in 367 patients with MS (326 relapse-onset and 41 progressive-onset) and 179 healthy controls. Expanded Disability Status Scale (EDSS) score was obtained at baseline and after a median follow-up of 5...
September 28, 2022: Journal of Neurology, Neurosurgery, and Psychiatry
#18
JOURNAL ARTICLE
Antonio Carotenuto, Paola Valsasina, Menno M Schoonheim, Jeroen Jg Geurts, Frederik Barkhof, Antonio Gallo, Gioacchino Tedeschi, Silvia Tommasin, Patrizia Pantano, Massimo Filippi, Maria A Rocca
BACKGROUND AND OBJECTIVES: In multiple sclerosis (MS), functional networks undergo continuous reconfiguration and topography changes over the disease course. Here, we aimed to investigate functional networks topography abnormalities in MS and their association with disease phenotype, clinical and cognitive disability, and structural MRI damage. METHODS: This is a multi-centre cross-sectional study. Enrolled subjects performed MRI, neurological and neuropsychological assessment...
September 12, 2022: Neurology
#19
JOURNAL ARTICLE
Isabelle Riederer, Mark Mühlau, Benedikt Wiestler, Benjamin Bender, Johann-Martin Hempel, Markus Kowarik, Thomas Huber, Claus Zimmer, Tiberiu Andrisan, Maximilian Patzig, Hanna Zimmermann, Joachim Havla, Ansgar Berlis, Lars Behrens, Meinrad Beer, Jennifer Dietrich, Nico Sollmann, Jan Stefan Kirschke
As a result of technical developments and greater availability of imaging equipment, the number of neuroradiological examinations is steadily increasing [1]. Due to improved image quality and sensitivity, more details can be detected making reporting more complex and time-intensive. At the same time, reliable algorithms increasingly allow quantitative image analysis that should be integrated in reports in a standardized manner. Moreover, increasing digitalization is resulting in a decrease in the personal exchange between neuroradiologists and referring disciplines, thereby making communication more difficult...
February 2023: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
#20
JOURNAL ARTICLE
Francesca Bagnato, Mitchell Wallin
Background: Magnetic resonance imaging (MRI) assists with the diagnosis of multiple sclerosis (MS), allows for timely therapeutic intervention, and for the evaluation of disease progression, treatment effect, and safety. An international task force including representatives from the Veterans Health Administration worked together to update guidelines for imaging the brain, spinal cord, and optic nerve in people with MS. Observations: This commentary communicates the core message of the 2021 MAGNIMS-CMSC-NAIMS Consensus Recommendations on the Use of MRI in Patients With Multiple Sclerosis as part of the MS Center of Excellence effort to align with contemporary guidelines, apply the highest scientific standards, and achieve consistent outcomes for veterans with MS...
April 2022: Federal Practitioner
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
